Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMPL-306 in Advanced or Metastatic Solid Tumors With IDH Mutations
NCT04762602Phase 1Terminated
- Sponsor
- HUTCHMED
- Start
- Feb 2021
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of ranosidenib in solid tumor (2 arms), sponsored by HUTCHMED. Primary endpoints: Recommended Phase 2 Dose at Day 28, Dose-limiting Toxicities at Day 28 and 1 more. Started Feb 2021; status: terminated.
02
Drugs
ranosidenib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04762602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04762602.